Drug Development

Product

Isoquercetin Formulation

  • Isoquercetin patented formulation (Kinisoquin™)
  • Isoquercetin prevents platelet activation and initiation of the thrombotic cascade.
  • Inhibits Tmem176b, VEGF, PDL-1, TF and P-Sel
  • Reduces tumor size and cancer markers better than CIS/GEM in cancer
  • Over 20’000 publications referencing Isoquercetin and Quercetin in multiple indications.
  • Safety profile of Kinisoquin™ (our main investigational drug) is well established. It has been shown not to increase bleeding risk – a significant advantage over Heparins and Direct Oral Anticoagulants

Isoquercetin-Zafirlukast Combination

  • Isoquercetin formulation with Zafirlukast patented and repurposed (the “Combo”)
  • Zafitrlukast has shown significant anti-cancer effects and is a PAN PDI inhibitor
  • Combo prevents thrombosis
  • Combo inhibits tumor growth in all solid cancers
  • Combo inhibits VEGF and PDL-1
  • Combo inhibits a series of other cancer and thrombosis markers including TF, Tmem176b and Tmem16

" While thrombosis is a major problem affecting cancer patients, the primary concern with currently available anticoagulants is the increased risk of hemorrhage. In randomized studies, the directoral anticoagulants effectively reduced the incidence of thrombosis but at a cost of doubling the rate of major hemorrhage. Developing an effective and safe antithrombotic agent would greatly improve adoption of primary prevention strategies in the cancer community. "

— Jeffrey Zwicker, MD Professor of Medicine
Chief of the Hematology Service at Memorial Sloan Kettering Cancer Center (MSK), New York, USA

Lead indication: VTE prevention in cancer

  • Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is an important cause of morbidity and mortality among patients with cancer.
  • Besides increased risk of VTE, advanced cancer patients have a significantly increased bleeding risk.
  • Major bleeds are a side effect of the anticoagulants in use today which include LMWH and DOACS which cause bruising and bleeding with other side effects.
  • As a result, Venous thromboembolism (VTE) prevention remains limited for advanced cancer patients, despite these patients being at a high risk of VTE.
  • Currently, anticoagulant use is not recommended for prophylactic use in cancer patients due to significantly increased bleeding risk.
  • Kinisoquin™ is expected to prevent VTE effectively without increased risk of bleeding in advanced cancer patients.

Pipeline indications and progress

  • Reduction of tumor metastasis (already proven in animal models)
  • Treatment of Ovarian Cancer and other solid tumors (already proven in animal models)
  • Treatment of Sickle Cell Disease (SCD) (shown in Phase 2 Published Clinical Trial Data in collaboration with NIH)
  • Treatment of Amyotrophic Lateral Sclerosis (ALS) (solid pre-clinical data)
  • Test for Thrombosis Risk (to be developed with a partner)
  • Other cancers and diseases with high risk of thrombosis (pre-clinical data)